


Dose Modification Guide for Amivantamab and Lazertinib


The information provided in this section summarizes dose modification guidance as described in the amivantamab¹ and lazertinib² prescribing information. These are not recommendations for individual patient care. Interventions should be based on patient presentation and the clinical judgment of the treating physician.

Dose Reductions of Amivantamab¹ and Lazertinib² for Adverse Reactions




Dose Modifications of Amivantamab¹ and Lazertinib² for Dermatologic AEs[†]

Dose Modifications of Amivantamab for Dermatologic AEs¹



Dose Modifications of Lazertinib for Dermatologic AEs²



Considerations for Amivantamab and Lazertinib Withholding and Restarting Treatment³

The information provided in this section summarizes interventions investigators in the MARIPOSA³ study were instructed to perform to monitor and manage rash. These are not recommendations for individual patient care. Interventions should be based on patient presentation and the clinical judgment of the treating physician.

-  If clinical observations indicate moderate toxicity and one treatment must be withheld, it is recommended to withhold amivantamab first, unless the toxicity is strongly suspected to be caused solely by lazertinib
-  If both treatments (eg, amivantamab and lazertinib) are stopped, they can be restarted once the toxicity has resolved. Generally, if both are to be continued, lazertinib should be restarted at least 7 to 14 days before the next amivantamab infusion to ensure the patient is stable on lazertinib alone

For dose modifications related to ILD/pneumonitis, IRRs, VTEs, and other adverse reactions, please refer to the full prescribing information for

 **RYBREVA** (Section 2.6) and  **LAZCLUZE** (Section 2.4)

AE, adverse event; HCP, health care practitioner; ILD, interstitial lung disease; IRR, infusion-related reaction; VTE, venous thromboembolism.
*Dose at which the adverse reaction occurred. [†]Dermatitis acneiform, pruritus, and dry skin. [‡]Including toxic epidermal necrolysis.

1. RYBREVA[®] [Prescribing information]. Horsham, PA: Janssen Biotech, Inc. 2. LAZCLUZE[™] [Prescribing information]. Horsham, PA: Janssen Biotech, Inc. 3. Yang JC-H, et al. *N Engl J Med*. Published online September 7, 2025. doi:10.1056/NEJMoa2503001. (supplement).